Abstract:Xi Tan, 1,* Yan Fang, 1,* Yuanyuan Ren, 1 Yinghuan Li, 2 Peicheng Wu, 3 Xiangliang Yang, 1,4 Wei Liu 1,4 1 College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan 430074, People's Republic of China; 2 School of Pharmaceutical Sciences, Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Capital Medical University, Beijing 100069, People's Republic of China; 3 School of Biosciences and Biopharmaceuticals, Institute of Biopharmaceuticals, Guangdong Pharmaceutical University, Guangzhou 510006, People's Republic of China; 4 National Engineering Research Center for Nanomedicine, Huazhong University of Science and Technology, Wuhan 430074, People's Republic of China * These authors contributed equally to this work Background: Combination therapy employing siRNAs and antitumor drugs is a promising method for the treatment of solid tumors. However, regarding combined treatments involving siRNAs and chemotherapeutic reagents, most prior research has focused on the enhanced cytotoxicity against tumor cells conferred by downregulation of the targeted protein. Purpose: We developed D-α-tocopherol polyethylene glycol 1000 succinate (TPGS)-modified cationic liposomes (LPs) to simultaneously deliver doxorubicin (Dox) and the Bcl-2 siRNA (siBcl-2) for synergistic chemotherapy. The co-loading of siBcl-2 onto the Dox-loaded cationic LPs (siBcl-2/Dox-TPGS-LPs) could promote cellular uptake, cytotoxicity against 3D H22 tumor spheroids, circulation in the blood, drug accumulation at tumor sites, and synergistic chemotherapy in vivo. Methods: The siBcl-2/Dox-TPGS-LPs were constructed by co-loading siBcl-2 onto the Dox-loaded TPGS-modified cationic LPs (Dox-TPGS-LPs), and Dox entrapment into the LPs was achieved using an ammonium sulfate gradient method. The antitumor effects of siBcl-2/Dox-TPGS-LPs were studied in murine hepatic carcinoma H22 cells, 3D H22 tumor spheroids, and H22 tumor-bearing mice. Results: Dynamic light scattering technique and transmission electron microscopy images revealed that siBcl-2 loaded onto the Dox-TPGS-LPs formed a prominent corona at an nitrogen to phosphorus (N/P) ratio of 4:1, resulting in particle size increase from 155 to 210 nm and a weak positive zeta potential (+12.5 mV). The siBcl-2/Dox-TPGS-LPs enhanced the cellular uptake of Dox, promoted toxicity against 3D H22 tumor spheroids via tumor priming, prolonged Dox circulation in the blood, and increased accumulation of Dox at tumor sites, thereby enhancing the cytotoxicity of Dox in vitro and its chemotherapeutic efficacy in vivo. Conclusion: The siBcl-2/Dox-TPGS-LPs demonstrated a strong potential for application in synergistic chemotherapy. The co-loading of siRNAs both sensitized cells toward antitumor drugs by downregulating the expression level of a specific protein and influenced the pharmacokinetic behavior of the co-delivery system in vitro and in vivo. Keywords: siRNA corona, cationic liposomes, co-delivery, Bcl-2, tumor priming, synergistic chemotherapy

Targeted-delivery of Sirna Via a Polypeptide-Modified Liposome for the Treatment of Gp96 Over-Expressed Breast Cancer.

Toxicological Exploration of Peptide-Based Cationic Liposomes in Sirna Delivery.

Highly Stable Polyglutamate Derivatives/sirna Polyplex Efficiently Down-Relegate Survivin Expression and Augment the Efficacy of Cisplatin.

Integrin Receptor-Mediated Strategy for Tumor Targeting Delivery of siRNA and Doxorubicin

Stimuli-Responsive Polysaccharide Enveloped Liposome for Targeting and Penetrating Delivery of survivin-shRNA into Breast Tumor

Co-Delivery of Doxorubicin and Survivin Shrna-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

Tumor-targeting Dual Peptides-Modified Cationic Liposomes for Delivery of Sirna and Docetaxel to Gliomas.

D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming

Hybrid Liposome-MSN System with Co-Delivering Potential Effective Against Multidrug-Resistant Tumor Targets in Mice Model

Co-delivery of Doxorubicin and P-glycoprotein Sirna by Multifunctional Triblock Copolymers for Enhanced Anticancer Efficacy in Breast Cancer Cells.

In Vitro Investigation of RGD-modified Stabilized Cationic Liposomes As Non-Viral Vehicle for Sirna Delivery

Co-Delivery of Doxorubicin and Plasmid by A Novel Fgfr-Mediated Cationic Liposome

Systemic Delivery of Sirna with Cationic Lipid Assisted PEG-PLA Nanoparticles for Cancer Therapy.

PEG Modified Trimethyl Chitosan Based Nanoparticles for the Codelivery of Doxorubicin and Isur-Pdna

Co-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors

Tumor-Targeting Peptide for Redox-Responsive Pt Prodrug and Gene Codelivery and Synergistic Cancer Chemotherapy.

Co-delivery of Doxorubicin and P-gp Sirna into Human Breast Cancer Cells by Functionalized PLGA Nanobubbles and Ultrasound Imaging in Vitro.

Enhancing Sirna-Based Cancer Therapy Using a New Ph-Responsive Activatable Cell-Penetrating Peptide-Modified Liposomal System

Cetuximab-Modified Human Serum Albumin Nanoparticles Co-Loaded with Doxorubicin and MDR1 siRNA for the Treatment of Drug-Resistant Breast Tumors

Cationic Micelle-Based Sirna Delivery for Efficient Colon Cancer Gene Therapy.

Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy